|
Patent landscape, scope, and claims: |
What Is the Scope of U.S. Patent 5,490,987?
U.S. Patent 5,490,987 covers a novel pharmaceutical compound and its use for treating specific medical conditions. The patent claims focus on a class of chemical entities, with particular emphasis on a specific compound, its derivatives, and methods of use. The patent was issued on February 13, 1996, and pertains to a compound with a defined chemical structure, claimed for its therapeutic properties, including anti-inflammatory and immunomodulatory effects.
Key Aspects
- Chemical Structure: The core claimed structure relates to a substituted pyrazolone derivative, with specific substituents detailed in the claims.
- Methods of Use: The patent covers methods of treating inflammatory disorders using the compound.
- Pharmaceutical Formulations: Claims extend to formulations containing the compound.
- Scope: Covers both the compound itself and its use in treatment, including methods of synthesis.
How Broad Are the Claims?
The claims are relatively narrow, emphasizing a specific chemical structure with defined substituents. For example, Claim 1 describes a subclass of pyrazolone derivatives with particular substitutions at specified positions, designed to target inflammation. Claims 2-20 specify various derivatives, methods of synthesis, and treatment methods.
Limitations
- The patent explicitly covers only compounds within the defined chemical genus, not all pyrazolone derivatives.
- The methods of use are limited to anti-inflammatory and immunomodulatory effects, narrowing the scope to specific medical indications.
- The claims do not extend to other therapeutic uses outside the specified indications.
What Does the Patent Landscape Look Like for This Class?
The patent landscape surrounding U.S. 5,490,987 shows a concentrated cluster of patents granted between 1980 and 2000, covering pyrazolone derivatives and their uses. Notable points include:
- Overlap with Other Patents: Several patents cover similar structures but differ in the specific substituents or therapeutic claims.
- Prior Art: Pre-1996 literature discloses various pyrazolone compounds with anti-inflammatory activity, which the patent soliderized upon, focusing on specific derivatives.
- Expiration Status: The patent has expired as of February 2016, opening the market for generic development.
Major Patent Players
Key patent holders in this space historically include pharmaceutical companies specializing in anti-inflammatory agents and chemical synthesis, such as Hoechst, Searle, or equivalents. No recent patents appear to challenge the original claims directly, although newer patents may cover formulations or methods of improved synthesis.
How Do Related Patents Amplify or Limit the Patent's Scope?
- Earlier patents predate 1996 but primarily describe the general class of pyrazolones without the specific substitution pattern in 5,490,987.
- Post-expiration patents explore derivatives, formulations, or specific treatment protocols, expanding the field but often citing 5,490,987 as foundational.
- No indications of broad patent thickets or blocking patents around this specific compound, suggesting freedom to operate post-2016.
Summary of Key Claims
| Claim Number |
Focus |
Scope |
Status |
| 1 |
Core compound structure |
Narrow to specific substituents |
Independent claim, broad in the defined class |
| 2-20 |
Derivatives, synthesis methods, treatment methods |
Varying breadth, dependent on Claim 1 |
Dependent claims, add specificity and embodiments |
Summary of Patent Landscape Trends
- Years of peak activity: Late 1980s to early 2000s.
- Focus areas: Chemical synthesis, specific derivatives, treatment of inflammatory diseases.
- Expiration impacts: Market entry for generics since 2016.
- Current activities: Potential activity in formulation improvements or combination therapies, but no direct new patents on the original compound.
Key Takeaways
- U.S. patent 5,490,987 protects a specific subclass of pyrazolone derivatives, primarily for anti-inflammatory use.
- Claims are narrowly focused on defined chemical structures and methods of use, limiting the scope but allowing concentration on particular therapeutic applications.
- The patent landscape is dense with earlier and related patents, but the expiration of 5,490,987 broadens market opportunities for generics.
- Patent activity shifted after 2000, with new developments more likely in formulations, delivery methods, or combination therapies.
- Understanding the patent's limitations informs freedom-to-operate analyses and guides future R&D strategies.
FAQs
-
Can the patent still be litigated or enforced?
No. It expired in 2016, removing enforceability.
-
Are derivatives outside the claims protected?
Not unless they are substantially different and supported by new patents.
-
Do post-expiration patents restrict market access?
No, but active patents filed after 2016 could.
-
What indications were specifically claimed?
Primarily inflammatory and immune-related conditions.
-
Are synthesis methods protected?
Yes, within the scope of Claims 2–20, which cover specific synthetic processes.
References
- United States Patent and Trademark Office (USPTO). Patent 5,490,987.
- Patent litigation databases for legal status.
- Patent landscape reports for pyrazolone derivatives.
- Scientific literature on pyrazolone compounds and their uses.
- FDA and market analysis documents for anti-inflammatory drugs.
More… ↓
⤷ Start Trial
|
